RAAS blockers such as angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) are the most commonly used drugs in patients with hypertension, heart failure, and chronic kidney disease as they provide end-organ protection and increase ACE2 expression responsible for vasodilatory effects [53, 54]. This evidence concerns the gene ACE and heart failure.